Conditions: Gastrointestinal Stromal Tumor
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 69
Healthy volunteers: no

Brief summary:
A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sunitinib or imatinib for approximately one year.

Detailed description:
The study prematurely discontinued on July 27, 2009 due to poor recruitment and operational futility as a result of changes in clinical practice. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: sunitinib malate intervention 2: imatinib mesylate
Intervention descriptions: intervention 1: 37.5 mg daily intervention 2: 800mg daily

Protocol document: